Literature DB >> 16738205

Matrix metalloproteases in aberrant fibrotic tissue remodeling.

Annie Pardo1, Moisés Selman.   

Abstract

Pulmonary fibrosis, the final result of a large variety of interstitial lung diseases, is characterized by an aberrant remodeling of extracellular matrix (ECM) with a profound disturbance of the normal lung architecture. This remodeling includes the exaggerated accumulation of ECM components in the interstitial and alveolar spaces and the disruption of the basement membranes. It has long been accepted that matrix metalloproteases (MMPs) play an important role in the pathogenesis of pulmonary fibrosis, but the exact mechanisms are not well characterized. Several MMPs are strongly up-regulated in human and experimental lung fibrosis, highlighting the dynamic nature of scarring within the lung. MMPs are collectively capable of cleaving all components of the ECM and basement membranes, but importantly, they also process bioactive mediators such as growth factors, cytokines, chemokines, and cell-surface receptors. Moreover, they participate in the initiation of proteinase cascades that impact much broader substrates. Consequently, MMPs may play a central role in several interrelated processes observed in fibrosis such as ECM remodeling, basement-membrane breakdown, epithelial-cell apoptosis, cell migration, and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16738205     DOI: 10.1513/pats.200601-012TK

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  93 in total

Review 1.  Etiopathogenesis of Trismus in Patients With Head and Neck Cancer: An Exploratory Literature Review.

Authors:  Radhu Raj; Krishnakumar Thankappan; Chandrasekhar Janakiram; Subramania Iyer; Anil Mathew
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2020-04-27

Review 2.  Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases.

Authors:  Thomas A Wynn
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

3.  miR-29 is a major regulator of genes associated with pulmonary fibrosis.

Authors:  Leah Cushing; Ping Ping Kuang; Jun Qian; Fengzhi Shao; Junjie Wu; Frederic Little; Victor J Thannickal; Wellington V Cardoso; Jining Lü
Journal:  Am J Respir Cell Mol Biol       Date:  2010-10-22       Impact factor: 6.914

Review 4.  MMPs as therapeutic targets--still a viable option?

Authors:  Barbara Fingleton
Journal:  Semin Cell Dev Biol       Date:  2007-07-06       Impact factor: 7.727

Review 5.  Myofibroblast repair mechanisms post-inflammatory response: a fibrotic perspective.

Authors:  Casimiro Gerarduzzi; John A Di Battista
Journal:  Inflamm Res       Date:  2016-12-31       Impact factor: 4.575

Review 6.  The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases.

Authors:  Tracy J Doyle; Victor Pinto-Plata; Danielle Morse; Bartolome R Celli; Ivan O Rosas
Journal:  Chest       Date:  2012-10       Impact factor: 9.410

Review 7.  Radiation-induced fibrosis: mechanisms and implications for therapy.

Authors:  Jeffrey M Straub; Jacob New; Chase D Hamilton; Chris Lominska; Yelizaveta Shnayder; Sufi M Thomas
Journal:  J Cancer Res Clin Oncol       Date:  2015-04-25       Impact factor: 4.553

8.  MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis.

Authors:  Marco Checa; Víctor Ruiz; Martha Montaño; Rafael Velázquez-Cruz; Moisés Selman; Annie Pardo
Journal:  Hum Genet       Date:  2008-10-14       Impact factor: 4.132

Review 9.  Interstitial lung diseases in children.

Authors:  Annick Clement; Nadia Nathan; Ralph Epaud; Brigitte Fauroux; Harriet Corvol
Journal:  Orphanet J Rare Dis       Date:  2010-08-20       Impact factor: 4.123

10.  Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF).

Authors:  Kathy Boon; Nathaniel W Bailey; Jun Yang; Mark P Steel; Steve Groshong; Dolly Kervitsky; Kevin K Brown; Marvin I Schwarz; David A Schwartz
Journal:  PLoS One       Date:  2009-04-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.